BioAge Labs, Inc. investors are advised to take note of the March 10, 2025, deadline to participate as a lead plaintiff in a securities lawsuit, announced by Rosen Law Firm. The lawsuit alleges that BioAge failed to inform investors about safety issues related to its drug candidate Azelaprag. BioAge halted its STRIDES Phase 2 study due to subjects exhibiting heightened liver enzyme levels, suggestive of possible risks. Notably, Rosen Law Firm has a track record of obtaining substantial settlements for investors, with over $438 million secured in 2019 alone.